José Molina

José Molina

Auto-generated profile, based on publicly available information

José Molina

Clinical Unit of Infectious Diseases Microbiology and Parasitology Virgen del Rocío University Hospital Seville Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
JCJosé M. Cisneros
José M. Cisneros
ONOlaf Neth
Olaf Neth
MGM.V. Gil-Navarro
M.V. Gil-Navarro
JLJ.A. Lepe
J.A. Lepe
FJF. Jiménez-Parrilla
F. Jiménez-Parrilla
JMJ. Molina
J. Molina
Over the last decade, an exponential increase in bacterial resistance has been observed worldwide [ 1 x 1 Nicolas-Chanoine, MH, Blanco, J, Leflon-Guibout, V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008; 61: 273–281 Crossref | PubMed | Scopus (522) | Google Scholar See all References , 2 x 2 Talan, DA, Krishnadasan, A, Gorwitz, RJ et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011; 53: 144–149 Crossref | PubMed | Scopus (179) | Google Scholar See all References , 3 x 3 Valencia, R, Arroyo, LA, Conde, M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009; 30: 257–263 Crossref | PubMed | Scopus (141) | Google Scholar See all References , 4 x 4 Yong, D, Toleman, MA, Giske, CG et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53: 5046–5054 Crossref | PubMed | Scopus (1170) | Google Scholar See all References ]. No new antibacterial agents are expected to be on the market until 2018 at the earliest [ 5 x 5 Bartlett, JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis. 2011; 53: S4–S7 Crossref | PubMed | Scopus (79) | Google Scholar See all References , 6 x 6 European Centre for Disease Prevention and Control EMA. ECDC/EMEA Joint Technical Report: the bacterial challenge: time to react. Available at: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf; 2009. ((last accessed 27 February 2013).) Google Scholar See all References ]. Furthermore, the overall societal costs of antibiotic resistance were estimated to be 1.5 billion €/year in the European Union [ 6 x 6 European Centre for Disease Prevention and Control EMA. ECDC/EMEA Joint Technical Report: the bacterial challenge: time to react. Available at: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf; 2009. ((last accessed 27 February 2013).) Google Scholar See all References 6 ]. Inappropriate use of antibiotics has been shown to be directly related to the increase of bacterial resistances [ 7 x 7 Livermore, DM. Minimising antibiotic resistance. Lancet Infect Dis. 2005; 5: 450–459 Abstract | Full Text | Full Text PDF | PubMed | Scopus (173) | Google Scholar See all References 7 ], as well as to significant increases in morbidity and mortality [ 8 x 8 Davey, PG and Marwick, C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect. 2008; 14: 15–21 Abstract | Full Text | Full Text PDF | PubMed | Scopus (63) | Google Scholar See all References , 9 x 9 Kumar, A, Ellis, P, Arabi, Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009; 136: 1237–1248 Crossref | PubMed | Scopus (505) | Google Scholar See all References , 10 x 10 Garnacho-Montero, J, Ortiz-Leyba, C, Herrera-Melero, I et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother. 2008; 61: 436–441 Crossref | PubMed | Scopus (119) | Google Scholar See all References ]. It is widespread in most health centres, and up to 50% of antibiotic treatments prescribed have been estimated to be incorrect [ 11 x 11 Dellit, TH, Owens, RC, McGowan, JE et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 15: 44 Google Scholar See all References 11 ]. All clinicians are potential antimicrobial prescribers; therefore the generalization of antibiotic misuse is likely to be due to a misbalance between the high level of knowledge required for the appropriate use of antibiotics and the scarce training offered in this respect to the practising clinician.

17 November 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
AGAna Belen Guisado-Gil
Ana Belen Guisado-Gil
CICarmen Infante-Domínguez
Carmen Infante-Domínguez
GPGermán Peñalva
Germán Peñalva
JPJulia Praena
Julia Praena
CRCristina Roca
Cristina Roca
OTOn behalf of the PRIOAM Team
On behalf of the PRIOAM Team
During the COVID-19 pandemic, the implementation of antimicrobial stewardship strategies has been recommended. This study aimed to assess the impact of the COVID-19 pandemic in a tertiary care Spanish hospital with an active ongoing antimicrobial stewardship programme (ASP). For a 20-week period, we weekly assessed antimicrobial consumption, incidence density, and crude death rate per 1000 occupied bed days of candidemia and multidrug-resistant (MDR) bacterial bloodstream infections (BSI). We conducted a segmented regression analysis of time series. Antimicrobial consumption increased +3.5% per week (p = 0.016) for six weeks after the national lockdown, followed by a sustained weekly reduction of −6.4% (p = 0.001). The global trend for the whole period was stable. The frequency of empirical treatment of patients with COVID-19 was 33.7%. No change in the global trend of incidence of hospital-acquired candidemia and MDR bacterial BSI was observed (+0.5% weekly; p = 0.816), nor differences in 14 and 30-day crude death rates (p = 0.653 and p = 0.732, respectively). Our work provides quantitative data about the pandemic effect on antimicrobial consumption and clinical outcomes in a centre with an active ongoing institutional and education-based ASP. However, assessing the long-term impact of the COVID-19 pandemic on antimicrobial resistance is required.

1 February 2013 in Journal of Infection
Verified
Journal Article
Closed access
JMJ. Molina
J. Molina
IPI. Peñuela
I. Peñuela
JLJ.A. Lepe
J.A. Lepe
AGAntonio Gutiérrez-Pizarraya
Antonio Gutiérrez-Pizarraya
MGM.J. Gómez
M.J. Gómez
JPJerónimo Pachón
Jerónimo Pachón

22 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJosé Molina
José Molina
CRClara María Rosso-Fernández
Clara María Rosso-Fernández
EMEnrique Montero-Mateos
Enrique Montero-Mateos
JPJosé Ramón Paño-Pardo
José Ramón Paño-Pardo
MSMaría Solla
María Solla
OTon behalf of the SHORTEN-2 trial team
on behalf of the SHORTEN-2 trial team
Background: Research priorities in Antimicrobial Stewardship (AMS) have rapidly evolved in the last decade. The need for a more efficient use of antimicrobials have fueled plenty of studies to define the optimal duration for antibiotic treatments, and yet, there still are large areas of uncertainty in common clinical scenarios. Pseudomonas aeruginosa has been pointed as a priority for clinical research, but it has been unattended by most randomized trials tackling the effectiveness of short treatments. The study protocol of the SHORTEN-2 trial is presented as a practical example of new ways to approach common obstacles for clinical research in AMS. Objective: To determine whether a 7-day course of antibiotics is superior to 14-day schemes for treating bloodstream infections by P. aeruginosa (BSI-PA). Methods: A superiority, open-label, randomized controlled trial will be performed across 30 Spanish hospitals. Adult patients with uncomplicated BSI-PA will be randomized to receive a 7 versus 14-day course of any active antibiotic. The primary endpoint will be the probability for the 7-day group of achieving better outcomes than the control group, assessing altogether clinical effectiveness, severe adverse events, and antibiotic exposure through a DOOR/RADAR analysis. Main secondary endpoints include treatment failure, BSI-PA relapses, and mortality. A superiority design was set for the primary endpoint and non-inferiority for treatment failure, resulting in a sample size of 304 patients. Conclusions: SHORTEN-2 trial aligns with some of the priorities for clinical research in AMS. The implementation of several methodological innovations allowed overcoming common obstacles, like feasible sample sizes or measuring the clinical impact and unintended effects. Trial registration: EudraCt: 2021-003847-10; ClinicalTrials.gov: NCT05210439.

15 November 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
ACAna Casado
Ana Casado
AGAdelina Gimeno
Adelina Gimeno
MAManuela Aguilar-Guisado
Manuela Aguilar-Guisado
MGManuel García
Manuel García
JRJesús Francisco Rodríguez
Jesús Francisco Rodríguez
JMJosé Molina
José Molina
This study evaluates the safety of early oral ambulatory treatment of adult patients diagnosed with bacteremia after their discharge from the emergency department. A cohort of 206 febrile ambulatory patients was assessed. Bacteremic low-risk patients were recommended an oral treatment and were compared with matched febrile non-bacteremic outpatients. Rates of 14-day mortality and unplanned re-consultations were similar and below 5% in both cohorts, highlighting the safety of oral therapy of low-risk bacteremia, even from its onset.

30 October 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OGOn behalf of the REIPI/GEIH study group
On behalf of the REIPI/GEIH study group
Guillermo CuervoGuillermo Cuervo
Guillermo Cuervo
MCMariana Camoez
Mariana Camoez
ESEvelyn Shaw
Evelyn Shaw
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
MPMiquel Pujol
Miquel Pujol
The aim of the study was to determine clinical and microbiological differences between patients with methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia (CRB) undergoing or not undergoing haemodialysis, and to compare outcomes. Prospective multicentre study conducted at 21 Spanish hospitals of patients with MRSA bacteraemia diagnosed between June 2008 and December 2009. Patients with MRSA-CRB were selected. Data of patients on haemodialysis (HD-CRB) and those not on haemodialysis (non-HD-CRB) were compared. Among 579 episodes of MRSA bacteraemia, 218 (37.7 %) were CRB. Thirty-four (15.6 %) were HD-CRB and 184 (84.4 %) non-HD-CRB. All HD-CRB patients acquired the infection at dialysis centres, while in 85.3 % of the non-HD-CRB group the infection was nosocomial (p < .001). There were no differences in age, gender or severity of bacteraemia (Pitt score); comorbidities (Charlson score ≥ 4) were higher in the HD-CRB group than in the non-HD-CRB group (73.5 % vs. 46.2 %, p = .003). Although there were no differences in VAN-MIC ≥1.5 mg/L according to microdilution, using the E-test a higher rate of VAN-MIC ≥1.5 mg/L was observed in HD-CRB than in non-HD-CRB patients (63.3 % vs. 44.1 %, p = .051). Vancomycin was more frequently administered in the HD-CRB group than in the non-HD-CRB group (82.3 % vs. 42.4 %, p = <.001) and therefore the appropriate empirical therapy was significantly higher in HD-CRB group (91.2 % vs. 73.9 %, p = .029). There were no differences with regard to catheter removal (79.4 % vs. 84.2 %, p = .555, respectively). No significant differences in mortality rate were observed between both groups (Overall mortality: 11.8 % vs. 27.2 %, p = .081, respectively), but there was a trend towards a higher recurrence rate in HD-CRB group (8.8 % vs. 2.2 %, p = .076). In our multicentre study, ambulatory patients in chronic haemodialysis represented a significant proportion of cases of MRSA catheter-related bacteraemia. Although haemodialysis patients with MRSA catheter-related bacteraemia had significantly more comorbidities and higher proportion of strains with reduced vancomycin susceptibility than non-haemodialysis patients, overall mortality between both groups was similar.